GoodRx Holdings, Inc. (NASDAQ:GDRX – Get Free Report) has earned an average rating of “Hold” from the fifteen research firms that are currently covering the stock, Marketbeat reports. Three equities research analysts have rated the stock with a sell recommendation, seven have assigned a hold recommendation and five have given a buy recommendation to the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $3.8542.
Several research analysts have weighed in on the company. Wall Street Zen downgraded GoodRx from a “buy” rating to a “hold” rating in a research note on Sunday, January 25th. The Goldman Sachs Group dropped their price target on GoodRx from $4.00 to $2.50 and set a “neutral” rating for the company in a research note on Monday, March 2nd. Leerink Partners restated an “outperform” rating and issued a $3.00 price target on shares of GoodRx in a research note on Thursday, February 26th. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of GoodRx in a research note on Friday, February 27th. Finally, Morgan Stanley decreased their price target on shares of GoodRx from $5.00 to $4.00 and set an “equal weight” rating on the stock in a research note on Thursday, December 18th.
Read Our Latest Stock Analysis on GoodRx
Institutional Trading of GoodRx
GoodRx Trading Up 1.4%
Shares of GDRX stock opened at $2.19 on Friday. GoodRx has a 52-week low of $1.77 and a 52-week high of $5.81. The company has a debt-to-equity ratio of 0.78, a quick ratio of 2.61 and a current ratio of 2.61. The firm has a market capitalization of $750.23 million, a PE ratio of 24.34, a PEG ratio of 1.49 and a beta of 1.47. The stock has a fifty day simple moving average of $2.18 and a two-hundred day simple moving average of $2.83.
GoodRx (NASDAQ:GDRX – Get Free Report) last issued its quarterly earnings results on Wednesday, February 25th. The company reported $0.09 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.09. GoodRx had a return on equity of 9.31% and a net margin of 3.82%.The business had revenue of $194.79 million during the quarter, compared to analyst estimates of $193.27 million. During the same quarter in the prior year, the business posted $0.09 EPS. GoodRx’s revenue for the quarter was down 1.9% compared to the same quarter last year. On average, analysts predict that GoodRx will post 0.13 EPS for the current fiscal year.
About GoodRx
GoodRx Holdings, Inc (NASDAQ: GDRX) operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.
In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.
Featured Articles
Receive News & Ratings for GoodRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GoodRx and related companies with MarketBeat.com's FREE daily email newsletter.
